Abstract
RTOG 0933 is a phase II trial of HC sparing during whole brain radiation therapy for brain metastases. Credentialing in the techniques of HC sparing, including HC contouring and intensity-modulated radiation therapy (IMRT) planning, was required of each physician and institution prior to enrolling patients. We report on the experience of these QA processes and the dosimetric impact of HC contouring variation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
